Sun Pharma’s $11.75 billion Organon acquisition was much bigger than a typical pharma deal. Once people looked past the ...

Shares of Zydus Lifesciences surged after the company reported its March quarter earnings. The drugmaker posted a ...

Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower.

The iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is the rare fund that has spent the past year being publicly threatened ...

Reported Consolidated quarterly numbers for Mankind Pharma are: Net Sales at Rs 3,442.93 crore in March 2026 up 11.81% from ...

One of Wall Street’s major firms just put its stamp of approval on a specialty pharma name that has been quietly rallying.

Fintel reports that on May 19, 2026, Citigroup initiated coverage of Ascendis Pharma A (NasdaqGS:ASND) with a Buy recommendation. Analyst Price Forecast Suggests 26.79% Upside As of May 14, 2026, the ...

Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon ...

Purdue Pharma, the bankrupted drug manufacturer at the center of the nation’s yearslong opioid epidemic, shut down May 1. The ...

Net Sales at Rs 2,581.82 crore in March 2026 up 21.41% from Rs. 2,126.59 crore in March 2025. Quarterly Net Profit at ...

Latitude Investment Management, an investment management firm, released its fourth-quarter 2025 investor letter. A copy of ...

The drugmaker’s on-market pharma portfolio, together with drugs for lupus, breast cancer and multiple sclerosis, should ...